Compounds for inhibition of fibroblast activation protein
US12371416B2 · kind B2 · utility
0Cited by
1References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 29, 2021 |
| Grant date | Jul 29, 2025 |
| Priority date | — |
| Expiry date | Jul 23, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D401/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Quinolinecarboxamide compounds of general formula I exceed the previously known FAP inhibitors in affinity and inhibitory effect. These agents can be used to specifically target tumours for diagnostic and therapeutic purposes, or for laboratory purposes in the study of endogenous FAP expression.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.